TY - JOUR
T1 - Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society
AU - Capelozzi, Vera Luiza
AU - Allen, Timothy Craig
AU - Beasley, Mary Beth
AU - Cagle, Philip T.
AU - Guinee, Don
AU - Hariri, Lida P.
AU - Husain, Aliya N.
AU - Jain, Deepali
AU - Lantuejoul, Sylvie
AU - Larsen, Brandon T.
AU - Miller, Ross
AU - Mino-Kenudson, Mari
AU - Mehrad, Mitra
AU - Raparia, Kirtee
AU - Roden, Anja
AU - Schneider, Frank
AU - Sholl, Lynette M.
AU - Smith, Maxwell Lawrence
N1 - Funding Information:
We thank Patricia Rieken Macedo Rocco, MD, PhD, head of the Laboratory of Pulmonary Investigation and professor of physiology at Federal University in Rio de Janeiro, Brazil, for her useful comments. Research was supported by the Sao Paulo Research Foundation (FAPESP) and the CNPq National Council for Scientific and Technological Development (grants 471939/2010-2 and 483005/2012-6).
PY - 2017/12
Y1 - 2017/12
N2 - Acute respiratory distress syndrome (ARDS) is a multifactorial syndrome with high morbidity and mortality rates, characterized by deficiency in gas exchange and lung mechanics that lead to hypoxemia, dyspnea, and respiratory failure. Histologically, ARDS is characterized by an acute, exudative phase, combining diffuse alveolar damage and noncardiogenic edema, followed by a later fibroproliferative phase. Despite an enhanced understanding of ARDS pathogenesis, the capacity to predict the development of ARDS and to risk-stratify patients with the disease remains limited. Biomarkers may help to identify patients at the greatest risk of developing ARDS, to evaluate response to therapy, to predict outcome, and to improve clinical trials. The ARDS pathogenesis is presented in this article, as well as concepts and information on biomarkers that are currently used clinically or are available for laboratory use by academic and practicing pathologists and the developing and validating of new assays, focusing on the assays' major biologic roles in lung injury and/or repair and to ultimately suggest innovative, therapeutic approaches.
AB - Acute respiratory distress syndrome (ARDS) is a multifactorial syndrome with high morbidity and mortality rates, characterized by deficiency in gas exchange and lung mechanics that lead to hypoxemia, dyspnea, and respiratory failure. Histologically, ARDS is characterized by an acute, exudative phase, combining diffuse alveolar damage and noncardiogenic edema, followed by a later fibroproliferative phase. Despite an enhanced understanding of ARDS pathogenesis, the capacity to predict the development of ARDS and to risk-stratify patients with the disease remains limited. Biomarkers may help to identify patients at the greatest risk of developing ARDS, to evaluate response to therapy, to predict outcome, and to improve clinical trials. The ARDS pathogenesis is presented in this article, as well as concepts and information on biomarkers that are currently used clinically or are available for laboratory use by academic and practicing pathologists and the developing and validating of new assays, focusing on the assays' major biologic roles in lung injury and/or repair and to ultimately suggest innovative, therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=85037058535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037058535&partnerID=8YFLogxK
U2 - 10.5858/arpa.2017-0115-SA
DO - 10.5858/arpa.2017-0115-SA
M3 - Article
C2 - 28613912
AN - SCOPUS:85037058535
SN - 0003-9985
VL - 141
SP - 1719
EP - 1727
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 12
ER -